Beretta Holding Gains Two Seats at Sturm Ruger After Proxy Fight

by | May 4, 2026

Sturm, Ruger & Co. Inc. (RGR) and Beretta Holding S.A. have reached a cooperation agreement granting Beretta the right to appoint two independent directors post-2026 Annual Meeting. This move follows Beretta’s campaign for boardroom change, highlighting governance and performance issues.

Key Terms of the Agreement
At-a-glance summary
Board Seat Two independent directors appointed by Beretta
Standstill Ends 30 days before 2029 Annual Meeting notice
Tender Offer Up to 15.05% shares at $44.80 each
Voting Support Beretta votes with board during standstill
Committee Assignment Equal rights for Beretta-appointed directors
Total Shareholder Return — RGR vs S&P 500
Horizon RGR S&P 500 Spread
1 Year CAGR +27.8% +29.0% -1.2pp
3 Years CAGR -7.8% +20.2% -27.9pp
5 Years CAGR -3.7% +11.6% -15.3pp
Source: Boardroom Alpha

Under the agreement, Beretta Holding will appoint two independent directors to Sturm Ruger’s board, contingent on maintaining certain ownership levels. Although the 2026 slate excludes these directors, Ruger will support their election in 2027 and 2028. Beretta’s tender offer aims to increase its stake to over 15%.

Ruger’s performance has lagged, with a 3-year CAGR of -7.79% against the S&P 500’s +20.16%. Beretta’s case focused on this underperformance and governance missteps, as previously highlighted by Boardroom Alpha in February.

The agreement introduces board refreshment with independent directors, addressing Beretta’s calls for stronger governance. These directors will receive equal committee rights, enhancing board accountability.

Beretta’s standstill agreement restricts proxy contests and requires voting alignment with Ruger’s board through 2029, barring certain exceptions. This cooperation aims to stabilize governance while allowing Beretta to increase its influence.

Shareholders should monitor how the new directors influence Ruger’s strategic direction and governance. Beretta’s increased stake and board presence could drive necessary reforms, aligning management more closely with shareholder interests.

Recent Analysis

Daily SPAC Update – May 4, 2026

Blueport + SingAuto and Galaxyedge + Rongcheng Group Deals announced late Friday. Pono Capital Four separate trading. Gigcapital 7 non-redemption agreement.

Weekly Boardroom & Executive Moves: May 1, 2026

This week, significant leadership changes occurred across several companies facing financial difficulties. Abbott Laboratories (ABT) and Agilon Health Inc (AGL) appointed new board members and executives amidst high activist risks and declining TSRs. Accuray Inc (ARAY) and ALT5 Sigma Corp (ALTS) also saw key executive departures and appointments as they navigate substantial TSR declines. These shifts highlight the ongoing challenges and strategic redirections needed to stabilize operations and improve shareholder value.

Daily SPAC Update – May 1, 2026

Two SPAC IPOs launched today, raising a total of $500 million. CH4 Natural Solutions Acquisition Corp (MTNE) secured $300 million, while Quantum Leap Acquisition Corp (QLEP) raised $200 million. Today, 2 SPAC IPOs raised $500M, led by CH4 Natural Solutions (MTNE) at $300M. This follows a surge of activity at the end of April.

Daily SPAC Update – April 30, 2026

Today, six SPACs debuted, raising a total of $965 million. General Catalyst Global Resilience Merger Corp (GCGR) led the pack with $350 million, followed by RRE Ventures Acquisition Corp. (RREV) at $250 million. Month-to-date, SPAC IPOs total 16, bringing in $2.65 billion, compared to 11 IPOs last month that raised $1.72 billion.

Daily SPAC Update – April 29, 2026

Collective Acquisition Corp. II (CAII) launched its $220 million IPO today, targeting high-potential sectors like technology and healthcare. In executive moves, Roger Bendelac was appointed CEO of both Drugs Made in America Acquisition Corp (DMAA) and Drugs Made in America Acquisition II Corp (DMII), with Saleem Elmasri as CFO. Meanwhile, General Purpose Acquisition Corp (GPAC) saw a significant decline of 22.9%, closing at $9.96, while Aimei Health Technology Co Ltd (AFJK) gained 2.7% to $46.12.

Subscribe to Boardroom Alpha Newsletters

Subscribe to Boardroom Alpha's research to receive the latest on governance, SPACs, and people.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.